Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

In vitro killing of nosocomial pathogens by acid and acidified nitrite.

Rao A, Jump RL, Pultz NJ, Pultz MJ, Donskey CJ.

Antimicrob Agents Chemother. 2006 Nov;50(11):3901-4.

2.

Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study.

Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN.

Clin Infect Dis. 2006 Nov 15;43(10):1272-6. Epub 2006 Oct 13.

PMID:
17051491
4.

Proton pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea.

Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC.

Aliment Pharmacol Ther. 2006 Aug 15;24(4):613-9.

5.

Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003.

McDonald LC, Owings M, Jernigan DB.

Emerg Infect Dis. 2006 Mar;12(3):409-15.

6.

Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Dial S, Delaney JA, Barkun AN, Suissa S.

JAMA. 2005 Dec 21;294(23):2989-95.

PMID:
16414946
7.

An epidemic, toxin gene-variant strain of Clostridium difficile.

McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN.

N Engl J Med. 2005 Dec 8;353(23):2433-41. Epub 2005 Dec 1.

8.

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, René P, Monczak Y, Dascal A.

N Engl J Med. 2005 Dec 8;353(23):2442-9. Epub 2005 Dec 1. Erratum in: N Engl J Med. 2006 May 18;354(20):2200.

9.

Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec.

Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L.

Clin Infect Dis. 2005 Nov 1;41(9):1254-60. Epub 2005 Sep 20.

PMID:
16206099
10.

Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients.

Al-Tureihi FI, Hassoun A, Wolf-Klein G, Isenberg H.

J Am Med Dir Assoc. 2005 Mar-Apr;6(2):105-8.

PMID:
15871884
11.

Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters.

Merrigan MM, Sambol SP, Johnson S, Gerding DN.

J Infect Dis. 2003 Dec 15;188(12):1922-7. Epub 2003 Dec 9.

PMID:
14673773
12.

Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea.

Cunningham R, Dale B, Undy B, Gaunt N.

J Hosp Infect. 2003 Jul;54(3):243-5.

PMID:
12855243
14.

Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea.

Kyne L, Sougioultzis S, McFarland LV, Kelly CP.

Infect Control Hosp Epidemiol. 2002 Nov;23(11):653-9.

PMID:
12452292
15.

Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile.

Kyne L, Hamel MB, Polavaram R, Kelly CP.

Clin Infect Dis. 2002 Feb 1;34(3):346-53. Epub 2001 Dec 17.

PMID:
11774082
16.
17.

Gastric acid suppression does not promote clostridial diarrhoea in the elderly.

Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K.

QJM. 2000 Mar;93(3):175-81.

PMID:
10751237
18.
19.

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

Johnson S, Samore MH, Farrow KA, Killgore GE, Tenover FC, Lyras D, Rood JI, DeGirolami P, Baltch AL, Rafferty ME, Pear SM, Gerding DN.

N Engl J Med. 1999 Nov 25;341(22):1645-51.

20.

Toxic bile acids in gastro-oesophageal reflux disease: influence of gastric acidity.

Nehra D, Howell P, Williams CP, Pye JK, Beynon J.

Gut. 1999 May;44(5):598-602.

Supplemental Content

Support Center